Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study.
- Resource Type
- Article
- Authors
- Huey, Ryan W; Shah, Aakash Tushar; Reddi, Honey V; Dasari, Priyadarsini; Topham, James T; Hwang, Hyunsoo; Dhillon, Nishat; Willett, Anneleis; Smaglo, Brandon G; Estrella, Jeannelyn S; Rashid, Asif; Matamoros, Aurelio; Overman, Michael J; Choquette, Linda; Omerza, Greg; Kelly, Kevin; Wang, Xuemei; Loree, Jonathan M; Rueter, Jens; Varadhachary, Gauri R
- Source
- JNCI: Journal of the National Cancer Institute. Aug2023, Vol. 115 Issue 8, p994-997. 4p.
- Subject
- *CANCER of unknown primary origin
*LONGITUDINAL method
*NUCLEOTIDE sequencing
- Language
- ISSN
- 0027-8874
Real-world evidence regarding the value of integrating genomic profiling (GP) in managing cancer of unknown primary (CUP) is limited. We assessed this clinical utility using a prospective trial of 158 patients with CUP (October 2016-September 2019) who underwent GP using next-generation sequencing designed to identify genomic alterations (GAs). Only 61 (38.6%) patients had sufficient tissue for successful profiling. GAs were seen in 55 (90.2%) patients of which GAs with US Food and Drug Administration–approved genomically matched therapy were seen in 25 (40.9%) patients. A change in therapy was recommended and implemented (primary endpoint of the study) in 16 (10.1%) and 4 (2.5%) patients of the entire study cohort, respectively. The most common reason for inability to implement the profiling-guided therapy was worsening of performance status (56.3%). Integrating GP in management of CUP is feasible but challenging because of paucity of tissue and aggressive natural history of the disease and requires innovative precision strategies. [ABSTRACT FROM AUTHOR]